U.S. small-cap stocks are “challenged” as Wall Street pushes out expectations for when the Federal Reserve may begin lowering interest rates due to concerns over persistent inflation, according to BofA Global Research.
Source link
smallcap
The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks
The Russell 2000 Index soared 12% in December, which might reflect investors’ exuberance about the state of the U.S. economy — it appears the Federal Reserve has won its battle against inflation.
But if you are looking to broaden your exposure to the stock market beyond the large-cap S&P 500
,
buying shares of a fund that tracks the Russell 2000 Index
might not be the best way to do it. This is because the Russell 2000 isn’t selective — it is made up of the smallest 2,000 companies by market capitalization in the Russell 300 Index
,
which itself is designed to capture about 98% of the U.S. public equity market.
A better choice might be the S&P Small Cap 600 Index
because S&P Global requires companies to show four consecutive quarters of profitability to be initially included in the index, among other criteria.
Below is a screen of analysts’ favorite stocks among the S&P Small Cap 600, along with another for the Russell 2000.
Watch for a “head fake”
Much of the small-cap buying in December might have resulted from covering of short positions by hedge-fund managers. This idea is backed by the timing of trading activity immediately following the Federal Open Market Committee’s announcement on Dec. 13 that it wouldn’t change its interest-rate policy, according to MacroTourist blogger Kevin Muir. The Fed’s economic projections released the same day also indicate three cuts to the federal-funds rate in 2024.
Heading into the end of the year, a fund manager who had shorted small-caps, and then was surprised by the Fed’s interest-rate projections, might have scrambled to buy stocks it had shorted to close-out the positions and hopefully lock in gains, or limit losses.
That buying activity and resulting pop in small-cap prices could set up a typical “head fake” for investors as the new year begins, according to Muir.
The long-term case for quality
Looking at data for companies’ most recently reported fiscal quarters, 58% of the Russell 2000 reported positive earnings per share, according to data provided by FactSet. In other words, hundreds of these companies were losing money. These might include promising companies facing “binary events,” such as make-or-break drug trials in the biotechnology industry.
In comparison, 78% of companies among the S&P Small Cap 600 were profitable, and 93% of the S&P 500 were in the black.
Here are long-term performance figures for exchange-traded funds that track all three indexes:
ETF | Ticker | 2023 | 3 years | 5 years | 10 years | 15 years | 20 years |
iShares Russell 2000 ETF | 17% | 7% | 61% | 99% | 428% | 365% | |
iShares Core S&P Small Cap ETF | 16% | 25% | 69% | 129% | 540% | 515% | |
SPDR S&P 500 ETF Trust | 26% | 34% | 108% | 210% | 629% | 527% | |
Source: FactSet |
An approach tracking the S&P Small Cap 600 has outperformed the Russell 2000 for all periods, with margins widening as you go further back.
Brett Arends: You own the wrong small-cap fund. How to get into a better one.
Looking ahead for quality… or not
For the first screen, we began with the S&P Small Cap 600 and narrowed the list to 385 companies covered by at least five analysts polled by FactSet. Then we cut the list to 92 companies with “buy” or equivalent ratings among at least 75% of the covering analysts.
Here are the 20 remaining stocks among the S&P Small Cap 600 with the highest 12-month upside potential indicated by analysts’ consensus price targets:
Company | Ticker | Share “buy” ratings | Dec. 29 price | Consensus price target | Implied 12-month upside potential |
Vir Biotechnology Inc. | VIR | 88% | $10.06 | $32.00 | 218% |
Arcus Biosciences Inc. | RCUS | 82% | $19.10 | $41.00 | 115% |
Xencor Inc. | XNCR | 92% | $21.23 | $39.83 | 88% |
Dynavax Technologies Corp. | DVAX | 100% | $13.98 | $24.80 | 77% |
ModivCare Inc. | MODV | 100% | $43.99 | $75.50 | 72% |
Xperi Inc | XPER | 80% | $11.02 | $18.20 | 65% |
Thryv Holdings Inc. | THRY | 100% | $20.35 | $32.75 | 61% |
Ligand Pharmaceuticals Inc. | LGND | 100% | $71.42 | $114.80 | 61% |
Green Plains Inc. | GPRE | 80% | $25.22 | $40.30 | 60% |
Patterson-UTI Energy Inc. | PTEN | 75% | $10.80 | $17.00 | 57% |
Ironwood Pharmaceuticals Inc. Class A | IRWD | 83% | $11.44 | $17.83 | 56% |
Catalyst Pharmaceuticals Inc. | CPRX | 100% | $16.81 | $26.20 | 56% |
Payoneer Global Inc. | PAYO | 100% | $5.21 | $8.00 | 54% |
Helix Energy Solutions Group Inc. | HLX | 83% | $10.28 | $15.00 | 46% |
Arlo Technologies Inc. | ARLO | 100% | $9.52 | $13.80 | 45% |
Pacira Biosciences Inc. | PCRX | 100% | $33.74 | $48.40 | 43% |
Privia Health Group Inc. | PRVA | 100% | $23.03 | $32.53 | 41% |
Semtech Corp. | SMTC | 92% | $21.91 | $30.90 | 41% |
Talos Energy Inc. | TALO | 78% | $14.23 | $20.00 | 41% |
Digi International Inc. | DGII | 100% | $26.00 | $36.14 | 39% |
Source: FactSet |
Any stock screen should only be considered a starting point. You should do your own research to form your own opinion before making any investment. one way to begin is by clicking on the tickers for more about each company.
Click here for Tomi Kilgore’s detailed guide to the wealth of information available for free on the MarketWatch quote page.
Moving on to the Russell 2000, when we narrowed this group to stocks covered by at least five analysts polled by FactSet, we were left with 936 companies. Among these, 355 have “buy” or equivalent ratings among at least 75% of the covering analysts.
Among those 355 stocks in the Russell 2000, these 20 have the highest implied upside over the next year, based on consensus price targets:
Company | Ticker | Share “buy” ratings | Dec. 29 price | Consensus price target | Implied 12-month upside potential |
Karyopharm Therapeutics Inc. | KPTI | 75% | $0.87 | $6.00 | 594% |
Rallybio Corp. | RLYB | 100% | $2.39 | $16.50 | 590% |
Vor Biopharma Inc. | VOR | 100% | $2.25 | $15.44 | 586% |
Tenaya Therapeutics Inc. | TNYA | 100% | $3.24 | $19.14 | 491% |
Compass Therapeutics Inc. | CMPX | 86% | $1.56 | $9.17 | 488% |
Vigil Neuroscience Inc. | VIGL | 88% | $3.38 | $18.75 | 455% |
Trevi Therapeutics Inc. | TRVI | 100% | $1.34 | $7.33 | 447% |
Inozyme Pharma Inc. | INZY | 100% | $4.26 | $21.00 | 393% |
Gritstone bio Inc. | GRTS | 100% | $2.04 | $10.00 | 390% |
Actinium Pharmaceuticals Inc. | ATNM | 83% | $5.08 | $23.36 | 360% |
Lineage Cell Therapeutics Inc. | LCTX | 86% | $1.09 | $4.83 | 343% |
Century Therapeutics Inc. | IPSC | 86% | $3.32 | $14.67 | 342% |
Acrivon Therapeutics Inc. | ACRV | 100% | $4.92 | $21.13 | 329% |
Avidity Biosciences Inc. | RNA | 100% | $9.05 | $37.50 | 314% |
Longboard Pharmaceuticals Inc. | LBPH | 100% | $6.03 | $24.17 | 301% |
Omega Therapeutics Inc. | OMGA | 100% | $3.01 | $12.00 | 299% |
Allogene Therapeutics Inc. | ALLO | 82% | $3.21 | $12.79 | 298% |
X4 Pharmaceuticals Inc. | XFOR | 86% | $0.84 | $3.26 | 289% |
Caribou Biosciences Inc. | CRBU | 89% | $5.73 | $22.25 | 288% |
Stoke Therapeutics Inc. | STOK | 78% | $5.26 | $19.33 | 268% |
Source: FactSet |
That’s right — this Russell 2000 list is all biotech. And in case you are wondering if any companies are on both lists, the answer is no.
Don’t miss: 11 dividend stocks with high yields expected to be well supported in 2024 per strict criteria
The Wall Street bull who called this year’s stock market rally says small-cap stocks could surge 50% over the next year
In January, most economists were convinced that stubborn inflation and rising interest rates would lead to an imminent recession, and Wall Street’s top minds were feeling bearish about 2023.
But Fundstrat Global Advisors cofounder Tom Lee was optimistic. The veteran market watcher, who previously served as JPMorgan’s chief equity strategist, argued that the S&P 500 was set to soar nearly 25% to between 4,750 and 4,800 by year-end.
It was an out-of-consensus call, given that forecasters surveyed by Bloomberg had a median year-end target of just over 4,000 for the blue-chip index. But Lee believed that the Fed’s interest rate hikes would be able to tame inflation without sparking a job-killing recession—the vaunted economic “soft landing” that historically has been hard to come by.
Now that call is looking pretty prescient. The labor market has proved its resilience this year; inflation has steadily dropped from its 2022 four-decade high; and the economy continues to grow. As a result, the S&P 500 is up over 23% year to date, just a few percentage points away from Lee’s year-end target.
After this monumental rise in stocks, which saw the Dow Jones industrial average hit a record high this week, some investors are beginning to wonder if there are any gains left to be had.
“The recent rally in the market has investors pricing in the perfect soft landing for the economy, without the pain of a recession,” David Donabedian, chief investment officer of CIBC Private Wealth US, said Friday. “This may not be realistic, however.”
Donabedian warned that even if it’s “all systems go” for markets in the near term, there are “lingering concerns about valuations and ultimately a scenario that may be too rosy.”
Lee, ever the bull, disagrees. And he has a recommendation for investors: Look to smaller companies for outperformance next year.
“In the next 12 months it seems like small-caps can be up 50%,” he told CNBC Friday, arguing the Russell 2000 index, which tracks U.S. stocks with an average market capitalization of just $2.8 billion, could rise from 1,996 to 3,000 by year-end.
How small-cap stocks could outperform in 2024
Next year will be all about fading inflation and interest rate cuts, according to Lee, and that should benefit the small-cap stocks that have been hit the hardest by rising borrowing costs. Small-caps tend to have higher leverage, which means the Fed’s interest rate hikes over the past 18 months have dramatically affected their bottom line.
As a result, the Russell 2000 is up just over 14% this year, compared to the S&P 500’s roughly 23% rise. But if inflation continues to fade in 2024, leading the Fed to cut interest rates as is now widely forecast, that could be a boon for small-caps. And Lee is convinced inflation has already been tamed.
“I think inflation is easily going to hit the 2% core target sometime next year, and sort of stay there,” he said.
He noted that consumers’ inflation expectations, a good predictor of actual inflation, are falling. Americans’ one-year inflation outlook sank to just 3.1% in the University of Michigan’s December consumer sentiment survey released last week, a marked drop from the 4.5% in November and the lowest level since early 2021.
Lee also argued that 60% of core inflation—a metric that excludes more volatile food and energy prices—comes from housing, cars, and car services, categories that are no longer seeing huge price jumps.
“Housing and cars alone account for 1.74 percentage points of the excess inflation. We’re at 1.6% of excess [inflation]. So literally those two things account for all the inflation,” he noted.
To his point, U.S. home prices rose just 4.7% year over year in November, while rent prices fell 2.1% from a year ago, according to Redfin data. New vehicle prices have also fallen for three consecutive months, according to Cox Automotive. And used car prices dropped 5.8% from a year ago in November, according to the Manheim Used Vehicle Value Index.
As long as housing inflation “stabilizes” at 6% and car prices continue to fall, Lee believes inflation will drop to the Fed’s 2% target and “stay there” in 2024.
For investors, this means small-caps that will benefit most from interest rate cuts present opportunity, especially given how cheap they are compared to larger peers. Lee noted that small-cap stocks are a particularly good buy relative to the value of the assets on their balance sheets, called book value.
“On a price-to-book basis, [small-caps] are trading at where they were in 1999, relative to the S&P. And that was the start of a 12-year outperformance cycle,” Lee said.
This story was originally featured on Fortune.com
Traders, investors still see opportunity in small-cap Chinese stocks: Stocktwits
Despite the opacity of China’s economy, small-cap Chinese stocks continue to attract attention, according to Stocktwits, a social platform for investors and traders.
“Investors still think they can play this high-stakes game of musical chairs,” Tommy Tranfo, head of community at Stocktwits, told MarketWatch.
Tranfo explained that one of the biggest challenges related to Chinese stocks is working out exactly what is happening in China. “It’s impossible to know what is true coming out of China,” he said. “Any financial news or data that comes out of China has so many grains of salt associated with it that it’s inedible.”
Related: Small-cap Chinese stocks spark meme-like buzz
Nonetheless, a host of small-cap Chinese stocks, notably TOP Financial Group Ltd.
TOP,
sparked meme-like attention earlier this year. Shares of the Hong Kong-based trading firm skyrocketed after they proved popular with the WallStreetBets group on Reddit.
TOP Financial’s stock has fallen 23.1% in the last three months, while shares of Huadi International Group Co.
HUDI,
another favorite, have fallen 22.2%. Shares of fellow buzzy Chinese small caps Addentax Group Corp.
ATXG,
and Magic Empire Global Ltd.
MEGL,
have fallen 79.7% and 25.9%, respectively, outpacing the S&P 500 index’s
SPX
decline of 0.8%.
But there’s still interest in Chinese stocks, according to Tranfo, who pointed to insurance-technology specialist Cheche Group Inc.’s
CCG,
recent merger with special purpose acquisition company Prime Impact. The combined company began trading on the Nasdaq on Sept. 18, with its stock surging more than 581% that day.
Related: Meme stock TOP Financial Group soars more than 890%, spurred on by the Reddit crowd
“When our community sees that kind of activity, they raise their eyebrows,” Tranfo said. “The interest [in these stock movements] is coming from traders, more so than investors. People are looking to quick opportunities.”
Some investors, however, are taking a long-term approach to certain Chinese stocks. “We have seen really amazing stuff from our community,” Tranfo said, citing the example of coffee chain Luckin Coffee Inc.
LKNCY,
which had what he called an “incredibly positive” IPO in 2019.
Luckin subsequently became been embroiled in a financial misconduct investigation that caused its stock to collapse. The Starbucks Corp.
SBUX,
rival was eventually delisted from the Nasdaq but is now trading over the counter.
Related: China’s economy is suffering, and consumers won’t open their wallets — except to see movies
In an attempt to find out what was happening at Luckin, some investors on the Stocktwits platform dived deep into the company’s operations. “What came about over the next few years was that we had people in our community go to mainland China,” Tranfo said, adding that the “boots on the ground” researchers tracked orders at Luckin stores and reported the data back to the Stocktwits community.
Set against this backdrop, Luckin was brought back to a penny stock and is now trading above $32, Tranfo said, while acknowledging that China poses a unique set of challenges to investors.
Last month officials in China said they would stop reporting youth unemployment data after months of spiraling increases, the Wall Street Journal reported. The move comesat a time when the Chinese economy faces multiple challenges, from a reported real-estate crunch to consumer-spending woes, all amid ongoing geopolitical tensions with the U.S.
But traders and investors on the Stocktwits platform are still finding ways to look beyond these issues and tap into Chinese stocks. “The commonality between these two groups of people is that they can ignore all the noise,” Tranfo said. “The ability to drown that out is like a superpower.”